Influencing Wound Healing Through the Application of Hyaluronic Acid With Perfluorodecalin and Physalis Angulata Extract After Split Skin Removal From the Thigh – A Study in “Split Wound Design”

Overview

The study will use a split wound design to investigate whether secondary wound healing can be accelerated and improved by the application of hyaluronic acid combined with perfluorodecalin and Physalis angulata extract.

Full Title of Study: “Influencing Wound Healing Through the Application of Hyaluronic Acid With Perfluorodecalin and Physalis Angulata Extract After Split Skin Removal From the Thigh – A Study in “Split Wound Design””

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Triple (Participant, Care Provider, Investigator)
  • Study Primary Completion Date: April 2020

Detailed Description

In oral and maxillofacial surgery, split skin is regularly removed to cover secondary defects. These defects occur, for example, in tumor patients after the removal of microsurgical radialis or fibular grafts for defect coverage or reconstruction, since the skin cannot be primarily closed there. Split skin is defined as a free skin graft made of epidermis and the upper parts of the dermis. The average thickness of the grafts is 0.2-0.8 mm. The thickness of the split skin determines the pigmentation structure and the quality of the graft. The thinner the split skin, the better the healing tendency and the less scar remains at the donor site. However, a disadvantage of thin split skin grafts is the stronger secondary shrinkage in the recipient region. Moderately thick grafts are hardly subject to scar shrinkage, but occasionally leave hypertrophic scars or keloids at the donor site. Split skin grafts with a thickness of 0.6-0.8 mm provide the best esthetic results, but have a poorer healing rate. The split skin can be removed with a dermatome. The ventrolateral proximal thighs and the inside and outside of the upper arms are particularly suitable as donor regions. In oral and maxillofacial surgery, a 0.4 mm thick split skin is usually removed from the ventrolateral thigh to cover the defect in the forearm or lower leg. The requirement at the split skin removal site is rapid healing with complete re-epithelialization. To achieve this, wound management is currently left to the clinic itself, as there is no evidence-based standard care. The technical literature only recommends moist wound management and rare dressing changes. A new product that promises faster healing and reduced scarring of these wounds is Ready Medical Post Treatment. This is an established preparation consisting of hyaluronic acid, perfluorodecalin and Physalis angulata extract. Studies have shown that both hyaluronic acid and perfluorodecalin can significantly improve the epithelialisation rate of wounds. The study will use a split wound design to investigate whether secondary wound healing can be accelerated and improved by the application of hyaluronic acid combined with perfluorodecalin and Physalis angulata extract.

Interventions

  • Drug: Ready Medical Post Treatment
    • Treatment of half of the wound with the product “ready medical post treatment” in addition to conventional treatment with moist dressings (Mepilex and Fixomull); on the 1st, 4th and 7th day after surgery, the product is applied to the wound and the dressing is changed
  • Device: Conventionell Treatment
    • Treatment of half of the wound with conventional moist dressings (Mepilex and Fixomull); a dressing change only takes place on the 7th day postoperatively

Arms, Groups and Cohorts

  • Active Comparator: Conventionell Treatment
    • After split skin removal, the wound is divided into 2 parts (=2 arms): 1st half: conventional treatment with moist dressings (mepilex and fixomull)
  • Experimental: Treatment with Ready Medical Post Treatment
    • After split skin removal, the wound is divided into 2 parts (=2 arms): 2nd half: conventional treatment with moist dressings (mepilex and fixomull) and additional treatment with ready medical post treatment

Clinical Trial Outcome Measures

Primary Measures

  • Effect of Ready Medical Post Treatment on wound healing after split skin removal
    • Time Frame: 6.5 month
    • Evaluation of the process control of wound healing (three-dimensional scans of the thigh) by surgeons and patients using questionnaire (wound assessment by “Patient and Observer Scar Assessment Scale”) Patient and Observer Scar Assessment Scale: Vancouver Scar Scale, surface area; patient assessments of pain, itching, color, stiffness, thickness, relief (Score from 5 (best) to 50 (worse)
  • Effect of Ready Medical Post Treatment on wound healing after split skin removal
    • Time Frame: 6.5 month
    • Evaluation of the process control of wound healing (three-dimensional scans of the thigh) by surgeons and patients using questionnaire (wound assessment by “Manchester Scar Scale”) Manchester Scar Scale: VAS (Visual Analog Scale) plus scar color, skin texture, relationship to surrounding skin, texture, margins, size, multiplicity (Score from 5 (best) to 18 (worse)

Participating in This Clinical Trial

Inclusion Criteria

  • Age between 18-90 years – Split skin removal at the thigh must be planned for the patients – Adult patients who are mentally and physically able to understand the importance and scope of the study and to follow up the study staff – Written informed consent before participating in the study Exclusion Criteria:

  • Patients suffering from a systemic disease (e.g. diabetes mellitus, anticoagulant therapy,…) – Patients taking immunosuppressive drugs that may affect wound healing – Patients suffering from skin diseases – Pregnant and/or lactating women. Women of childbearing age should protect themselves from potential pregnancy by adequate contraception while participating in studies. – Participation in a study may, at the investigator's discretion, present an unacceptable risk due to pre- or concomitant disease or the patient's general underlying condition. – Underage, or older than 90 years – Life span is less than six months – There is a current or past medically relevant disease or treatment that could influence the evaluation of the study – The patient has received a study medication within the last 30 days as part of another study – Simultaneous participation in another clinical intervention study – Expected lack of compliance – Alcohol or drug abuse – The patient is accommodated in an institution by official or court order – Patients in a dependent relationship or employment relationship with the sponsor, investigator, or alternate investigator

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 90 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • RWTH Aachen University
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.